Slimming with pharmacology

I try my best but to no avail. I already know that the process of losing weight is arduous and difficult. I look at pharmacology with an increasingly greedy eye and I place more and more hope in it, envying my colleagues.

I experienced that the usual rule of less eat food did not bring any beneficial effects, but only led to the further progress of obesity through the yo-yo effect.

Obesity will not go away on its own, it tends to come back, progresses if left untreated and is associated with many dangerous complications.

Pharmacology

Today we have on hand:

1/LIRAGLUTYD/Saxenda/- subcutaneously/s.c./

2/NALTREKSON + BUPROPIN/Mysimba/- orally/p. o./

3/ORLISTAT/Xenical/- orally/p. o./

4/SEMEGLUTYD/Ozempic and his oral twin sister Rybelsus/. Ozempik - subcutaneously/s.c./, Rybelsus - orally/p.o./

I reject medicinal products not approved in the European Union.

1/LIRAGLUTYD - is an acylated analog of human glucagon-like peptide 1 (GLP-1), in which the amino acid sequence is 97% consistent with the amino acid sequence of the endogenous human GLP-1 molecule. Liraglutide binds to and activates the GLP-1 receptor (GLP-1R). GLP-1 controls appetite and food consumption under physiological conditions, but its exact mechanism of action is not fully understood.

2/NALTREXONE + BUPROPION - the neurochemical mechanisms underlying the appetite suppressant effect of naltrexone + bupropion are not fully known. The medicinal product in question consists of two active substances: naltrexone, a mu-opioid antagonist, and bupropion, a weak inhibitor of neuronal reuptake of dopamine and norepinephrine. Both of these active substances act on two major areas of the brain, namely the arcuate nucleus of the hypothalamus and the mesolimbic dopaminergic reward system.

3/ORLISTAT - is a strong, specific and long-acting inhibitor of lipases produced in the gastrointestinal tract. It acts in the lumen of the stomach and small intestine after it binds to the active serine site of gastric and pancreatic lipase. Inactive, the enzyme does not hydrolyze the fat ingested in the form of triglycerides to the resorbable free fatty acids and monoglycerides.

4/SEMAGLUTYDE - acts as an agonist of the GLP-1 receptor; selectively binds to the GLP-1 receptor and activates it, similar to native GLP-1. GLP-1 is a physiological hormone with multiple effects in regulating appetite, glucose concentration and cardiovascular function. Its effect on glucose levels and appetite are related to the GLP-1 receptors found in the pancreas and brain. Semaglutide lowers blood glucose in a glucose dependent manner by stimulating insulin secretion and by reducing glucagon secretion when blood glucose levels are high. The mechanism of blood glucose lowering also involves a slight delay in early gastric emptying after a meal. Semaglutide reduces body weight and fat mass by reducing caloric intake, including suppressing appetite, and reduces the craving for high-fat foods.